Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...
Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We ...
Johnson & Johnson's JNJ.N prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and reduced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results